- Late Friday, the FDA cancelled its scheduled committee meeting to review the BLA for Heplisav.
- JPM says it spoke to management, and heard the following:
- DVAX expects to have outstanding questions from the FDA in the next several weeks. It did not speculate on the nature of the questions.
- "In our view, the nature of the questions will remain an overhang on DVAX shares."
- More of JPM's client note here.
- Currently DVAX is changing hands premarket at $12.51, 15% above its Friday close when it dropped 31.5%.